Impact of obstructive sleep apnea syndrom on clinical outcome in patients treated with drug-eluting stent for coronary artery disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002673

Enrollment

Unknown

Registered

2012-11-13

Start date

2013-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

OSAS:Loading dose of clopidogrel

no OSAS:Loading dose of clopidogrel

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged to be 18 to 75 years; 2. Patient (or patients legally-authorized representative) understands the trial requirements and treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed; 3. Patient is eligible for PCI; 4. Patient is willing to comply with all protocol-required follow-up evaluations.

Exclusion criteria

Exclusion criteria: 1. diagnosed the obstructive sleep apnoea syndrome and use of continuous positive airway pressure (CPAP); 2. mechanical ventilation with Endotracheal intubation; 3. sleep by sedatives before polysomnography; 4. high risk of malignant ventricular arrhythmia; 5. cardiac shock; 6. clinical heart failure needing oxygen therapy ; 7. Pregnancy; 8. Can't sign informed consent.

Design outcomes

Primary

Measure	Time frame
PL-MAR;	—

Countries

China

Contacts

Public ContactShao-Liang Chen

chmengx@126.com+86 13605157029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026